Overview

A Study To Taste Three New Types Of Crizotinib Formulation In Comparison Of An Oral Solution And To Measure The Amount Of Crizotinib In The Body After These Formulations Are Orally Given, Relative To Capsule Formulation

Status:
Completed

Trial end date:
2014-03-01

Target enrollment:

Participant gender:

Summary

This study is intended to evaluate the sensory attributes and estimate the relative bioavailability of three prototype oral formulations. Subjects will either taste 75-mg doses by "swirl and spit" (Cohort 1) or will receive five oral single 250-mg doses with a washout period of at least 14 days (Cohort 2).

Phase:

Phase 1

Details

Lead Sponsor:

Pfizer

Treatments:

Crizotinib
Pharmaceutical Solutions